



2015 First Quarter Results

12[™] May ,2015



This document has been prepared by NATURHOUSE HEALTH S.A. ("NATURHOUSE" or the "Company") for its exclusive use during the presentations announcing the Company's results for the first quarter of 2015. NATURHOUSE does not authorise its dissemination, publication or use by any other person, whether physical or legal, to an end other than that which has been expressed above, unless they have prior express consent in writing from NATURHOUSE, and neither does it, consequently, accept any responsibility for the content of the document if it is used to an end other than that expressed above without the authorisation of the Company.

Readers are warned that the information in this document has not been audited by the Company's auditors and it has been summarised. The information and the opinions and statements contained in this document have not been verified by independent third parties and, unless another source is expressly mentioned, they have been drawn up by the Company.

This document contains forecasts and estimates relating to the business progress or results of the Company in the future. These forecasts respond to the current opinion and expectations of NATURHOUSE HEALTH, S.A. These forecasts, that are uncertain by nature, are affected by risks, including those mentioned in the prospectus for the IPO and the offering and listing of NATURHOUSE shares, approved by the CNMV (Spanish stock exchange commission) and recorded in its official register on 9 April 2015, and it is available to investors on the issuer's website (www.naturhouse.com) and that of the CNMV (www.cnmv.es). These risks may cause real results to be significantly different to said forecasts or estimates.

The contents of this document must be taken into account by all individuals or entities that may have to make decisions or draw up or disseminate opinions regarding shares issued by NATURHOUSE HEALTH SA, and in particular by the analysts that make use of this document.

This document is not an offer of sale or subscription and neither is it an invitation to subscribe to or acquire NATURHOUSE shares or any other securities in Spain or in any other jurisdiction.





- 1. Main figures
- 2. Key Points for the Quarter
- 3. Consolidated Profit & Loss Account
- 4. Consolidated Balance Sheet



Growth in the company's main indicators, driven by the positive behaviour of the international market

| | 1Q14 | 1Q15 | % |
|---------------|--------|--------|-------|
| Sales | 23,901 | 24,253 | 1.5% |
| EBITDA | 7,913 | 8,547 | 8.0% |
| EBITDA Margin | 33.1% | 35.2% | |
| Net income | 5,184 | 5,820 | 12.3% |
| Centres | 1,954* | 2,004 | 50 |
| Countries | 24 | 27 | 3 |

In thousands of euros

Note: growth in these indicators cannot be extrapolated to the rest of the year due to the seasonal effect. Traditionally, the second quarter of the year makes the greatest contribution to the Group's accounts.

^{*}figure as of December 2014



Net Profits increased by 12.3% in the first quarter of 2015 +50 more net store openings (2,004 centres), equivalent to 80% of total net openings in 2014

| □ Nat | urhouse has registered net profits of €5.82m, up from €5.18m in 1Q14 (+12.3%) due to: |
|-------|---|
| | √The positive progress of the international market, driven by growth in France, Poland and Belgium, |
| | ✓ Operational efficiency policies, of which a 5.1% reduction in procurement costs (in spite of an increase in sales) has been especially significant, |
| | √The contribution of Ichem, a Polish company in which the group has a 24.9% stake, to the value of €0.3m (+28.4% vs 1Q14). |
| | FDA has increased by 8% to €8.55m vs €7.9m in 1Q14. The EBITDA margin stands at 35.2% (33.1% in 1Q14), placing it above per threshold of the company's guidance (30%-35%) for 2015 and 2016. |
| □Sale | s have climbed to €24.2m from €23.9 of 1T14. |
| | ew record in the company's history in terms of the number of centres (2,004 vs 1,925 for 1Q14 and 1,954 at the end of 2014) puntries (27). |
| | ✓ Centres: 2,004 at the end of 1Q15, after registering 50 net openings during the period, equivalent to 80% of total net openings for 2014. Of these openings, 90% are franchises, 8% master franchises and 2% directly-operated-stores, which underlines the Group's capacity for growth in line with its franchise-based growth strategy. |
| | ✓ Countries: Naturhouse operates in 27 countries compared to 24 in 1Q14, following the addition of Russia, Panama and Switzerland. |





| | 1Q14 | 1Q15 | Growth (%) |
|--|--------|--------|------------|
| Sales | 23,901 | 24,253 | 1.5% |
| Procurements | -7,405 | -7,026 | -5.1% |
| Gross profit | 16,496 | 17,227 | 4.4% |
| Gross profit margin | 69.0% | 71.0% | |
| Personnel | -3,773 | -4,416 | 17.0% |
| Other operating expences | -4,836 | -4,489 | -7.2% |
| Other Income | 26 | 225 | 765.4% |
| EBITDA | 7,913 | 8,547 | 8.0% |
| EBITDA Margin | 33.1% | 35.2% | |
| Amortization & Impairments | -319 | -415 | 30.1% |
| EBIT | 7,594 | 8,132 | 7.1% |
| EBIT Margin | 32% | 34% | 481% |
| Financial results | -264 | -108 | -59.1% |
| Share of profit (loss) of associated (Ichem) | 229 | 294 | 28.4% |
| EBT | 7,559 | 8,318 | 10% |
| Taxes | -2,375 | -2,498 | 5.2% |
| Net profit | 5,184 | 5,820 | 12.3% |
| Net profit margin | 21.7% | 24.0% | |
| In the coord of course | | | |

In thousand of euros

Note: Variation in the "other operational expenses" item is due to a Kiluva, S.A. management fee in 2014 that is included in this section and which is no longer present in 2015. The "Personnel" section in 2015 includes the chairman's salary, which did not exist in previous financial years.



| | 2014 | 1Q15 |
|------------------------------------|--------|--------|
| Intangible assets | 2,345 | 2,343 |
| Property, plant & equipement | 5,522 | 5,281 |
| Non -current financial assets | 757 | 714 |
| Investment in associated companies | 2,749 | 3,043 |
| Deferred tax assets | 458 | 482 |
| Non current Assets | 11,831 | 11,863 |
| Inventories | 3,925 | 3,909 |
| Trade receivables | 5,564 | 7,338 |
| Other current assets | 683 | 561 |
| Investement in related companies | 11,007 | 903 |
| Financial assets | 42 | 42 |
| Cash & equivalents | 8,659 | 8,330 |
| Current assets | 29,880 | 21,083 |
| | | |

| TOTAL ASSETS | 41,711 | 32,946 |
|--|--------|--------|
| Equity | 15,371 | 8,385 |
| Non-current provisions | 798 | 808 |
| Non-current borrowings | 4,363 | 4,363 |
| Long term accrued expences | 456 | 166 |
| Non current liabilities | 5,617 | 5,337 |
| Current borrowings | 4,525 | 3,102 |
| Financial liabilities with related companies | 2,007 | 2,714 |
| Suppliers | 4,621 | 4,175 |
| Suplier related companies | 6,369 | 4,076 |
| Current tax liabilities and other payables | 3,201 | 5,157 |
| Current liabilities | 20,723 | 19,224 |
| TOTAL LIABILITIES | 41,711 | 32,946 |

In thousans of euros

- □A 16% reduction in gross financial debt (- €1.4m)
- □Reduction in the debt with Kiluva SA to €0.9m. As forecast, this item has been settled with the funds received by Kiluva SA during the IPO
- □ A dividend has been paid on 2015 profits to the value of €11.05m (€8.5m almost completely charged to the profits of Naturhouse Health SA subsidiaries in the 2014 financial year and the rest charged to profits accrued in 2015 by Naturhouse Health SA and its subsidiary corporations until 16 March)
- □Net cash position of €1.8m at end of 1Q15



CONTACT

María Pardo Martinez Investor Relations Manager

Tel: +34 914323953

Email: accionista@naturhouse.com